Shire (SHP) Stock Price Down 0%

Shares of Shire PLC (LON:SHP) dropped 0% on Monday . The stock traded as low as GBX 3,622.50 ($48.76) and last traded at GBX 3,646.50 ($49.08). Approximately 1,690,367 shares changed hands during trading, a decline of 40% from the average daily volume of 2,830,000 shares. The stock had previously closed at GBX 3,646.50 ($49.08).

SHP has been the subject of several recent analyst reports. Berenberg Bank restated a “buy” rating and set a GBX 6,000 ($80.75) price objective on shares of Shire in a research report on Wednesday, August 9th. Barclays downgraded shares of Shire to an “equal weight” rating in a research report on Friday, August 11th. Liberum Capital reduced their price target on shares of Shire from GBX 4,900 ($65.95) to GBX 4,400 ($59.22) and set a “hold” rating for the company in a research report on Friday, August 11th. Shore Capital reiterated a “buy” rating on shares of Shire in a research report on Tuesday, August 15th. Finally, Citigroup reiterated a “buy” rating and issued a GBX 6,300 ($84.79) price target on shares of Shire in a research report on Tuesday, August 22nd. Four analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of GBX 5,277.78 ($71.03).

In other news, insider Anne Minto acquired 190 shares of the company’s stock in a transaction on Friday, September 29th. The shares were bought at an average cost of GBX 3,785 ($50.94) per share, with a total value of £7,191.50 ($9,679.00).

WARNING: This piece was originally published by Transcript Daily and is owned by of Transcript Daily. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The correct version of this piece can be read at

Shire Company Profile

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with's FREE daily email newsletter.

Leave a Reply